HR Execs on the Move


 
SGS is the world`s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 95,000 employees, SGS operates a network of over 2,400 offices and laboratories around the world.
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion
  • www.sgs.com
  • 201 Route 17 North
    Rutherford, NJ USA 07070
  • Phone: 201.508.3000

Executives

Name Title Contact Details
G�raldine Picaud
Chief Financial Officer Profile
Tim Gooch
North America Technical Director ISO13485, MDSAP, Supply Chain, Medical Devices Profile
Michael Dell
Assistant General Counsel, Labor and Employment NAM Profile
Fulvio Martinez
Director of Marketing and Communications North America Profile
Journey Williams
SVP of Business Development and R&D Profile

Similar Companies

Southwest FLA Regional Imaging

Southwest FLA Regional Imaging is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brijen Biotech

Brijen Biotech is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellular Genomics

Cellular Genomics, Inc. is a Branford, CT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Arcellx

Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx`s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx`s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, expected to enter the clinic in the second half of 2022.

Biomet Microfixation

Founded by Walter Lorenz more than thirty years ago, Biomet Microfixation manufactures a complete range of craniomaxillofacial products, including LactoSorb, the first completely resorbable fixation system available in the U.S. Other products include